CelltiGraft

CELLTIGRAFT®

CELLTIGRAFT® is an Autologous Bilayer Tissue Engineered Human Skin (TEHS) used to treat and manage skin loss injury and wounds. It is completely compatible with patients with zero chance of rejection.
CELLTIGRAFT® is constructed of 1 to 2 millions of fibroblasts and keratinocytes cells which are embedded in human plasma.

CELLTIGRAFT® is applicable as an alternative in the treatment of:​​

  • Huge skin loss due to major burns
  • Non-healing or recurring ulcers
  • Full thickness skin loss due to trauma 
  • Skin loss due to other medical causes

HOW IS CELLTIGRAFT® PRODUCED?

  • CELLTIGRAFT® can be constructed from a single 1 x 3 cm elliptical skin biopsy then processed with enzymes to produce fibroblasts and keratinocytes. These cells are extracted, cultured and expanded.​
  • HPD extracted from patient’s own blood (autologous) is used as the biomaterial scaffold for constructing the CelltiGraft . This process creates the 3-Dimensional structure of CelltiGraft  providing the ideal bilayer skin substitute for treating skin loss.
  • The cell culturing process will only take 4 to 6 weeks for producing 1 to 2 millions of fibroblasts and keratinocytes cells per 100 cm2 skin construct.

CELLTIGRAFT® TRANSPLANTATION METHOD

  • Sterile environment is required for implantation of CELLTIGRAFT® preferably inside of sterile Operation Theater.
  • Before implantation of CELLTIGRAFT®, a few nick had to be done using scalpel for fenestration of blood or serous from surgical wound site.
  • CELLTIGRAFT® can be secured at the implanted site using absorbable suture or staple.
  • HPD extracted from patient’s own blood (autologous) is used as the biomaterial scaffold for constructing the CelltiGraft . This process creates the 3-Dimensional structure of CelltiGraft  providing the ideal bilayer skin substitute for treating skin loss.
  • The cell culturing process will only take 4 to 6 weeks for producing 1 to 2 millions of fibroblasts and keratinocytes cells per 100 cm2 skin construct.

celltigraft®​ CASE STUDY

COMPARISON OF CELLTIGRAFT® AND MYDERM®​

CHARACTERISTICS
MYDERM®​
​CELLTIGRAFT®​
Number of Cells
More
Less
​​Duration to Construct
​Approx. 6 weeks
​Approx. 3 weeks
​HPD Biomaterial
Yes
Yes
​Ingredients
​​Fibroblast and Keratinocytes
Fibroblast and Keratinocytes
​Scaffold
​Patient’s Own Blood
Patient’s Own Blood
Autologous
Yes
Yes
​Associated with Growth Factors
More
Less
​ Mimic Native Skin
Yes
Yes
​Preservation & Re-culture
Yes
Yes
​Permanent Skin Substitute
Yes
Yes
Number of Surgery
One
One
​SSG Procedure
No
No
Source of Substance
​Patient’s Own Cells
​​Patient’s Own Cells

WHY CHOOSE CELLTIGRAFT®

  • Autologous, so unlikely to cause any rejection or immunological reaction.
  • Bilayer characteristic in CELLTIGRAFT® means it mimics the native skin layer of the dermis and epidermis.
  • HPD biomaterial used in CELLTIGRAFT® production is made of natural molecule which is also autologous and will easily degrade into the body host after implantation.
  • Functions as a permanent coverage of wound.
  • Able to cover a large wound without the need to harvest from big donor area.
  • Able to restore the barrier function of damaged or burned skin.
  • Has the ability to secrete growth factors, enzymes and biochemical to mimic the physiological activity of the skin, hence promote rapid wound healing.
  • Results in better cosmesis by improving the quality of scarring and pigmentation.

INDICATION FOR CELLTIGRAFT®

  • CELLTIGRAFT® is used in a wide variety of skin loss due to trauma, burning, chronic non-healing ulcer, orthopedic, and also in plastic and reconstructive surgery.

PRODUCT DELIVERY

  • CELLTIGRAFT® is delivered and stored inside a cooler box to maintain the temperature between 4℃ to 8℃ in sterile package.
  • CELLTIGRAFT® must be used within 24 hours at temperature between 4℃ and to 8℃​.
  • CELLTIGRAFT® handling is strictly under aseptic precaution.

SHELF LIFE

  • CELLTIGRAFT® must be used within 3 DAYS from its final construct date.

CITATIONS

1. Law, J. X., Chowdhury, S. R., Aminuddin, B. S., & Ruszymah, B. H. I. (2017). Role of plasma-derived fibrin on keratinocyte and fibroblast wound healing. Cell and tissue banking18(4), 585-595.

2. Idrus, R. H., bin P Rameli, M. A., Low, K. C., Law, J. X., Chua, K. H., Latiff, M. B. A., & Saim, A. B. (2014). Full-thickness skin wound healing using autologous keratinocytes and dermal fibroblasts with fibrin: bilayered versus single-layered substitute. Advances in Skin & Wound Care27(4), 171-180.

3. 
Busra M. F., Chowdhury S. R., bin Ismail F., bin Saim A., Idrus R. B. (2016). Tissue-engineered skin substitute enhances wound healing after radiation therapy. Advances in skin & wound care29(3), 120-129.


4. Maarof, M., Law, J. X., Chowdhury, S. R., Khairoji, K. A., Saim, A. B., & Idrus, R. B. H. (2016). Secretion of wound healing mediators by single and bi-layer skin substitutes. Cytotechnology68(5), 1873-1884.

5. Law, J. X., Musa, F., Ruszymah, B. H. I., El Haj, A. J., & Yang, Y. (2016). A comparative study of skin cell activities in collagen and fibrin constructs. Medical engineering & physics38(9), 854-861.

6. Ishak, M.F., Maarof, M., Ng, M.H., Khairul, B., Gargy, L., Aminuddin, B.S. (2019).Long Term Effect of Cryopreservation on Primary Human Skin Cells. Sains Malaysiana, 48 (1), 137-144.